Jaydess (Levonorgestrel)

Levonorgestrel acts on progesterone receptors in the cervical mucus and endometrium. It thickens cervical mucus, inhibits the growth of the uterine lining, and suppresses the mid‑cycle surge of luteinizing hormone, thereby preventing ovulation and creating conditions unfavorable for sperm penetration and implantation.

Jaydess is supplied as a single intrauterine system containing 13.5 mg of levonorgestrel. The device is inserted by a qualified health professional and provides contraceptive effect for up to three years. The exact dosing schedule and timing of replacement are determined by the prescribing clinician.

Jaydess is classified as Pregnancy Category X, meaning it must not be used in women who are pregnant. It is intended for women who are not pregnant at the time of insertion. Breastfeeding women should discuss alternative contraceptive options with their health‑care provider, as levonorgestrel may be present in small amounts in breast milk.

To request Jaydess, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details and any required import documentation.

Jaydess and other levonorgestrel‑based IUS devices, such as Mirena, share a similar mechanism and efficacy. Jaydess contains 13.5 mg of levonorgestrel and is approved for up to three years of use, whereas some alternatives may have different hormone loads or approved durations. Choice between products depends on clinical judgment, patient preference, and regulatory approvals in the target market.

Jaydess should be stored at ambient temperature, below 25 °C, in its original packaging. It must be protected from moisture, direct sunlight and extreme temperature fluctuations to maintain device integrity until insertion.

Jaydess is inserted into the uterine cavity by a trained health‑care professional using a sterile insertion device. The procedure is performed in a clinical setting, typically after confirming the patient is not pregnant and any active pelvic infection has been treated.

Serious risks include uterine perforation during insertion, expulsion of the device after placement, and pelvic infection such as tubo‑ovarian abscess. Although rare, these complications require prompt medical evaluation and may necessitate removal of the IUS.

Jaydess is contraindicated in women who are pregnant, have active pelvic infections, known or suspected breast cancer, severe liver disease, unexplained vaginal bleeding, or uterine anomalies that could impede proper placement. Patients with a history of thromboembolic disorders should also discuss alternative contraception with their clinician.